According to a recent LinkedIn post from Ro, the company is introducing new savings for patients paying cash for Wegovy, with potential savings cited at up to $1,200 per year. The post indicates that, by working with Novo Nordisk, Ro aims to offer what it describes as the lowest available cash prices for this FDA-approved GLP-1 treatment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post further suggests that Ro plans to pair these lower GLP-1 prices with additional savings opportunities on its forthcoming Body membership. This emphasis on affordability and bundled care could support user acquisition and retention in the competitive weight-management and telehealth markets, potentially strengthening Ro’s recurring revenue profile and strategic positioning in GLP-1–driven obesity care.